Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $45.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price increased by The Goldman Sachs Group from $36.00 to $45.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also weighed in on the stock. Scotiabank lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, December 22nd. Truist Financial increased their target price on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $37.11.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $34.29 on Monday. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $37.35. The firm has a market capitalization of $39.32 billion, a PE ratio of 28.57, a PEG ratio of 1.96 and a beta of 0.70. The business’s 50 day moving average is $31.86 and its 200-day moving average is $24.24. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Activity

In other news, insider Mark Sabag sold 216,892 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director owned 367,600 shares in the company, valued at approximately $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 422,060 shares of company stock worth $12,254,965. 0.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Allworth Financial LP increased its position in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust lifted its position in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $41,000. Finally, Global Retirement Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.